AI startup Owkin scores $180M to advance oncology pipeline

French artificial intelligence (AI) and precision medicine startup Owkin startup has achieved unicorn status, after scoring a $180 million (€135M) investment from pharma firm Sanofi.

The two companies will also collaborate on discovery and development programmes for breast cancer, lung cancer, mesothelioma and multiple myeloma, with a total payment of $90 million (€79.7M) for three years plus additional research milestone-based payments.

Arnaud Robert, executive vice president and chief digital officer at Sanofi, said: “Owkin’s unique methodology, which applies AI on patient data from partnerships with multiple academic medical centres, supports our ambition to leverage data in innovative ways in R&D.” MobiHealthNews